Innovative Product Portfolios Ride Commercialization & Global Expansion - Research Report on Amgen, Onyx Pharmaceuticals, Ale...

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Amgen Inc. (NASDAQ: AMGN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Amgen Inc. Research Report

As one of the most consistently traded stocks among biotechnology companies, Amgen has been strategically outlining and delivering its approach to long-term growth and profitability. Aside from improving shareholder value, Amgen is committed to discovering, innovating, developing and manufacturing breakthrough treatments for unheeded illnesses.  Amgen is capitalizing on major advances in drug discovery and biologics manufacturing as it boosts its product pipeline. The company reported that one of its key strategies for growth and profitability is international expansion and commercialization. Amgen is expected to penetrate new and emerging markets as it expands its access and value to payers or end-users. The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/e763_AMGN]

--

Onyx Pharmaceuticals, Inc. Research Report

With a vision to grow from a company with three therapies and four indications to an industry leader, Onyx Pharmaceuticals is gearing up its operations as it aims to reach more patients globally. The strong growth of Onyx Pharmaceuticals last year was a solid basis for the company's near-term momentum for sustainability. Investors are bullish that the company can achieve its goals as it continues to rake in revenues and royalties amid its expansion. Onyx Pharmaceuticals is preparing for US commercialization as it scouts for opportunities in the international market. The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/fcf8_ONXX]

--

Alexion Pharmaceuticals, Inc. Research Report

Being the second most innovative company in Forbes' annual ranking, analysts and investors are optimistic about the future of Alexion Pharmaceuticals as it continues to advance its nine lead development programs for Soliris and four additional innovative therapeutics. Alexion Pharmaceuticals continues to see steady growth for Soliris as it continues the global commercialization of the drug. The company is keen on expanding its global presence amid Soliris' approval for patients with paroxysmal nocturnal hemoglobinuria (PNH) in US, European Union and Japan. Alexion Pharmaceuticals also acquired the rights for the first potential treatment for hypophosphatasia (HPP), and is currently advancing the first-in-class targeted enzyme replacement therapy to Phase II clinical trials. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/451f_ALXN]

--

BioMarin Pharmaceutical Inc. Research Report

With increased efforts for research and development, BioMarin Pharmaceuticals is growing its business by boosting its commercial portfolio. BioMarin Pharmaceuticals' product pipeline has helped the company surpass its $500 million revenue. The company believes that its portfolio will continue to propel the company while improving shareholder value. BioMarin Pharmaceuticals' reported that it expects to receive the first regulatory approval for Vimizim by the end of this year. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/936c_BMRN]

--

Incyte Corporation Research Report

The quarter-over-quarter growth of Incyte last year highlights the company's growth potential as it continues to deploy its financial strategies. Incyte is expecting an increase in research and development as the company partners with Lilly for the Phase III study of baricitinib. In a 2013 financial guidance report, Incyte also highlighted its $66 million milestone payment for Jakafi under the Novartis and Lilly collaborative agreements. Analysts and investors have high hopes in the company as it possesses growth potential in the international market. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WallStSource.com/r/full_research_report/0762_INCY]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Joe Thomas
Email: [e-mail]
Main: [phone] (North America)

SOURCE Wall Street Source

Copyright 2013 PR Newswire